MIAMI AND LOS ANGELES — Talent Testing Service Inc. (TTS) on Wednesday said it welcomes the move by Manwin on adopting new performer testing standards.
Starting July 1, the adult entertainment conglomerate is requiring tests from clinics listed on the APHSS.org website, including those that use the HIV-1 Aptima RNA Qualitative Assay.
“Talent Testing Service has been offering the HIV-1 Aptima RNA Qualitative Assay testing since 2006 as part of our company philosophy to provide the most accurate and reliable testing to the industry,” said Sixto Pacheco, president and CEO of TTS. “The implementation of this methodology in 2006 by TTS was a welcomed addition to our product offering which continues to evolve as new technologies emerge."
TTS uses QR codes for validating printed test results, as well as a convenient mobile page for verification of authenticity on-demand and access to actual test results. Producers, agents and talent are provided with personal online dashboards that provides access to historical and most recent testing information at no cost. Performers also can set up automatic reminders for their next test dates.
To facilitate clients the accessibility to its testing program, TTS has more than 300 drawing sites across the U.S. staffed with licensed professionals. TTS provides same-day test results for clients who visit its Miami office before noon, and 24-hour test results for clients who visit the other 300 facilities.
With yesterday's announcement, Manwin also is mandating that tests be no older than 15 days for all performers and third-party producers hired to create its content.
